Last updated: August 6, 2026
Trimethoprim sulfate and polymyxin B sulfate ophthalmic solution is an established topical antibacterial combination with limited remaining exclusivity barriers and a mature generic market. The commercial opportunity is primarily formulation-led: preservative-free delivery, improved tolerability, unit-dose packaging, differentiated multidose containers, and supply reliability. The core formulation is technically constrained by preservative compatibility, pH control, microbial protection, and the need to maintain activity of two chemically different antibacterial agents.
The reference product, Polytrim ophthalmic solution, contains trimethoprim sulfate equivalent to 1 mg/mL trimethoprim and polymyxin B sulfate equivalent to 10,000 units/mL polymyxin B. Its labeled inactive ingredients include benzalkonium chloride, sodium chloride, hydrochloric acid and sodium hydroxide for pH adjustment, and purified water [1].
What is the formulation of trimethoprim sulfate and polymyxin B sulfate ophthalmic solution?
The product is an aqueous ophthalmic solution for topical treatment of susceptible bacterial eye infections.
| Component |
Typical role or concentration |
| Trimethoprim sulfate |
Equivalent to 1 mg/mL trimethoprim |
| Polymyxin B sulfate |
10,000 units/mL |
| Benzalkonium chloride |
Preservative, approximately 0.004% in the reference formulation |
| Sodium chloride |
Tonicity adjustment |
| Hydrochloric acid and sodium hydroxide |
pH adjustment |
| Purified water |
Vehicle |
Trimethoprim is a weak base with limited aqueous solubility that is improved through salt formation. Polymyxin B sulfate is a cationic cyclic polypeptide antibiotic supplied as a sulfate salt. The combination therefore requires a formulation environment that maintains both solubility and antimicrobial potency without generating visible precipitation, adsorption losses, or excessive ocular irritation.
The product is generally formulated near physiological osmolality and at a pH tolerated by the eye. The label specifies storage at controlled room temperature and protection from contamination during use [1].
What excipients are protected or commercially important in the reference product?
The main excipient value is functional rather than proprietary. The reference formulation uses a conventional ophthalmic platform, but each excipient performs a critical role.
Benzalkonium chloride
Benzalkonium chloride provides multidose antimicrobial preservation. It is commercially effective at low concentrations and compatible with many aqueous ophthalmic products. Its principal limitation is ocular-surface tolerability. Repeated exposure can contribute to epithelial disruption, dryness, inflammation, and discomfort, particularly in patients with chronic ocular-surface disease or prolonged treatment.
A preservative-free version would therefore have a clear commercial rationale, but it would require a different container-closure strategy and a validated microbial risk-control program.
Sodium chloride
Sodium chloride adjusts tonicity and helps reduce stinging. Tonicity can also influence protein or peptide behavior, although polymyxin B is not a conventional protein biologic. Excessive ionic strength may affect aggregation, adsorption, or container interactions.
Hydrochloric acid and sodium hydroxide
These agents adjust and maintain pH during manufacture. A robust formulation process must control pH after addition of both sulfate salts, after sterilization, and over shelf life. pH drift may affect trimethoprim solubility and polymyxin B stability.
Purified water
Water quality is a critical manufacturing attribute. The product requires validated sterile processing or aseptic manufacture, tight bioburden controls, and a container system that prevents microbial ingress during repeated dosing.
What formulation patents protect trimethoprim and polymyxin B ophthalmic products?
The commercial product is unlikely to have meaningful active patent protection in the United States. Polytrim was approved decades ago, and the product’s core composition is a conventional aqueous combination of two established antibiotics.
The FDA Orange Book identifies the reference product under NDA 050592. Public FDA product information does not indicate a current exclusivity period that would block generic competition, and the product is available through multiple generic suppliers [2]. The key intellectual-property risk is therefore not the basic combination but potentially narrower patents covering:
- Preservative-free delivery systems.
- Unit-dose or multidose container designs.
- Low-irritation preservative systems.
- Specific pH or osmolality ranges.
- Improved stability against polymyxin adsorption.
- Manufacturing processes that increase yield or reduce degradation.
- Novel gels, emulsions, suspensions, or sustained-release ocular inserts.
- Combination use with other ophthalmic agents.
A new formulation patent would need meaningful technical differentiation. Claims limited to replacing one conventional excipient with another may face written-description, enablement, obviousness, or lack-of-unexpected-results challenges.
When does trimethoprim and polymyxin B lose exclusivity?
Core U.S. market exclusivity expired long ago. The reference product has no current new-drug exclusivity that prevents ANDA competition.
| Exclusivity or IP category |
Current commercial significance |
| Core composition patent |
Not a material barrier based on the product’s age |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No current blocking period identified |
| Orphan exclusivity |
Not applicable |
| FDA Orange Book patents |
No active blocking patent identified in the cited FDA materials |
| Generic ANDA pathway |
Available |
| Biosimilar pathway |
Not applicable |
Generic applicants can generally rely on the reference product through an ANDA, subject to demonstrating pharmaceutical equivalence, bioequivalence where applicable, manufacturing compliance, sterility, stability, and labeling conformity.
How many patents cover the product, and which companies are challenging it?
The core product does not appear to depend on an active patent thicket. Generic competition is established, and the principal U.S. regulatory pathway is abbreviated approval rather than patent litigation.
Publicly available FDA materials do not identify a current Paragraph IV dispute that materially blocks generic entry for the base ophthalmic solution. The relevant competitive activity is commercial substitution among generic suppliers rather than patent litigation.
Potential applicants and suppliers include established ophthalmic manufacturers and contract manufacturers with sterile-fill capabilities. The competitive advantage is more likely to come from manufacturing scale, shortage avoidance, pharmacy contracting, and container differentiation than from a Paragraph IV strategy.
What FDA regulatory status applies to trimethoprim and polymyxin B?
The product is an FDA-approved prescription ophthalmic antibacterial. The reference product is listed under NDA 050592, while generic versions are approved through ANDAs referencing the listed drug [1,2].
An ANDA sponsor must address:
- Strength and dosage form.
- Active ingredient identity and concentration.
- Sterility assurance.
- Container-closure integrity.
- Stability and in-use performance.
- Preservative effectiveness for multidose presentations.
- Extractables and leachables.
- Particulate matter and visible inspection.
- Labeling and administration instructions.
A formulation that changes inactive ingredients may still qualify for an ANDA if the change does not affect safety, efficacy, performance, or pharmaceutical equivalence. A materially different delivery system could require a 505(b)(2) application rather than a conventional ANDA.
What excipient strategy creates the strongest commercial opportunity?
1. Preservative-free unit-dose solution
This is the clearest differentiation route. Single-use vials eliminate the need for benzalkonium chloride and reduce preservative exposure.
Commercial targets include:
- Dry-eye patients.
- Postoperative patients receiving multiple topical medicines.
- Pediatric patients.
- Contact-lens intolerant patients.
- Patients receiving repeated or prolonged courses.
- Hospitals and ambulatory surgery centers seeking low-contamination packaging.
The principal disadvantages are higher packaging cost, greater fill-finish complexity, more waste, and potentially lower pharmacy gross margin.
2. Preservative-reduced or alternative-preserved multidose product
A multidose product using a less irritating preservative could offer a cost advantage over unit-dose packaging. Candidate systems may include stabilized oxychloro complexes, polyquaternium-based preservatives, or other ophthalmic preservation technologies.
The formulation must establish preservative effectiveness without compromising polymyxin B. Cationic or surfactant-like preservatives may interact with the cationic polymyxin molecule, creating a specific compatibility risk. Screening must include potency, adsorption, turbidity, particle formation, and antimicrobial activity over shelf life.
3. Low-irritation formulation
A low-stinging product can compete without changing the active ingredients. Possible levers include:
- Narrow pH optimization.
- Improved buffering control.
- Tonicity adjustment.
- Reduced preservative burden.
- Lower extractables from the container.
- Reduced drop volume.
- Optimized viscosity without impairing drainage or vision.
Claims based only on patient comfort may require clinical support if used in promotional positioning.
4. Multidose preservative-free container
A preservative-free multidose bottle could combine convenience with improved ocular-surface tolerability. This opportunity depends on proprietary one-way valves, filtered dispensing, tip protection, or airless packaging.
The patent value would lie in the container and microbial-barrier system rather than in the drug composition. Regulatory development would require container-closure integrity, in-use microbial challenge testing, dose uniformity, drop-size characterization, and compatibility data.
5. Improved supply and hospital presentation
The product is suitable for hospital and outpatient procedural channels. Commercial opportunities include:
- Unit-dose cartons.
- Small-volume institutional packs.
- Barcoded packaging.
- Tamper-evident closures.
- Reliable short-lead-time supply.
- Dual sourcing of sterile-fill capacity.
For a mature generic, supply reliability can be more valuable than minor formulation changes, particularly where competitors experience manufacturing interruptions.
What manufacturing and IP barriers affect market entry?
The principal barrier is sterile ophthalmic manufacturing, not active pharmaceutical ingredient access.
Manufacturing risks
Polymyxin B sulfate can present challenges involving:
- Lot-to-lot potency variation.
- Complex component distribution.
- Adsorption to manufacturing equipment or packaging.
- Sensitivity to pH and ionic conditions.
- Visible and subvisible particles.
- Sterilization and aseptic-processing controls.
Trimethoprim sulfate introduces separate risks involving solubility, precipitation, and pH-dependent stability. The finished product must maintain both active ingredients within specification throughout shelf life.
Container risks
Low-density polyethylene bottles, low-density polypropylene components, elastomer closures, and unit-dose plastics can interact with the formulation. Extractables and leachables, adsorption, closure permeability, and drop-size consistency require evaluation.
IP risks
A new entrant could obtain meaningful protection around:
- Specific container-valve systems.
- Preservative-free multidose dispensing.
- Stabilized polymyxin formulations.
- Defined pH and tonicity combinations with unexpected stability.
- Manufacturing processes that reduce potency loss.
- Combination products with corticosteroids or lubricants.
Broad claims to the active combination are likely to be vulnerable because the ingredients and ophthalmic use are established.
How does this product compare with competing ophthalmic antibiotics?
| Product class |
Main advantage |
Main limitation |
| Trimethoprim/polymyxin B |
Broad topical coverage, established safety, low cost |
Mature generic market and limited differentiation |
| Tobramycin |
Familiar aminoglycoside option |
Resistance and aminoglycoside tolerability considerations |
| Fluoroquinolone ophthalmics |
Broad bacterial coverage and convenient dosing |
Greater stewardship pressure and often stronger resistance concerns |
| Erythromycin ophthalmic ointment |
Ointment retention and neonatal use |
Blurred vision and narrower practical use |
| Besifloxacin or other branded agents |
Branded formulation and positioning |
Higher acquisition cost |
| Combination antibiotic-steroid products |
Anti-inflammatory benefit in selected cases |
Steroid-related safety risks and narrower prescribing context |
Trimethoprim/polymyxin B competes most effectively where low acquisition cost, established labeling, and uncomplicated aqueous dosing matter. A preservative-free or low-irritation presentation could improve its position in patients who would otherwise receive alternative agents because of ocular-surface concerns.
What revenue exposure and launch scenarios exist?
Public FDA sources do not provide product-level revenue for Polytrim or individual generic suppliers. Revenue exposure is best assessed through prescription volume, payer substitution, channel mix, and supply position rather than through patent timing.
| Launch scenario |
Likely positioning |
Commercial outlook |
| Conventional preserved generic |
Lowest-cost substitution |
High competition, limited margin |
| Preservative-free unit dose |
Ocular-surface and institutional use |
Higher price potential, higher packaging cost |
| Low-irritation multidose |
Retail and chronic ocular-surface segments |
Moderate differentiation |
| Preservative-free multidose |
Premium convenience and tolerability |
Stronger IP potential, greater development risk |
| Hospital-focused pack |
Surgery centers and inpatient use |
Contract-driven, supply reliability critical |
| 505(b)(2) sustained delivery |
Reduced dosing frequency |
Higher development cost and regulatory burden |
A conventional ANDA launch is the lowest-risk entry strategy but offers limited pricing power. A differentiated delivery system can command a premium if it demonstrates improved tolerability, handling, contamination control, or adherence.
What is the litigation and settlement outlook?
The litigation outlook for the base product is limited because the core formulation is old and generic competition is established. A new branded or reformulated product could create disputes over:
- Infringement of container patents.
- Obviousness of preservative-free or low-irritation formulations.
- ANDA paragraph IV certifications against later patents.
- Trade dress and labeling.
- Product-specific manufacturing patents.
- Antitrust issues involving supply or distribution agreements.
No material settlement agreement is identified in the cited FDA materials for the basic trimethoprim sulfate and polymyxin B sulfate ophthalmic solution. Any settlement involving a later proprietary formulation would need separate review of court dockets and patent-family records.
Key Takeaways
- The core trimethoprim sulfate and polymyxin B sulfate ophthalmic solution is a mature, largely off-patent product.
- The reference formulation uses benzalkonium chloride, sodium chloride, pH adjusters, and purified water.
- Preservative-free unit-dose delivery is the most practical commercial differentiation.
- A preservative-free multidose container offers greater margin and patent potential but carries higher technical and regulatory risk.
- Polymyxin B compatibility, adsorption, pH stability, sterility, and container performance are the main development constraints.
- The base product has limited Paragraph IV and litigation value.
- A conventional ANDA supports rapid low-cost entry but exposes the sponsor to intense generic competition.
- The strongest IP opportunity lies in dispensing systems, stability improvements, and tolerability-focused formulations.
- Biosimilar risk is irrelevant because this is a small-molecule antibacterial combination, not a biologic.
- Geographic opportunities depend on local registration, preservative requirements, antibiotic procurement, and sterile manufacturing capacity.
FAQs About Trimethoprim Sulfate and Polymyxin B Sulfate Commercialization
Can benzalkonium chloride be removed without changing the regulatory pathway?
Possibly. A preservative-free presentation may remain eligible for an ANDA if the product remains pharmaceutically equivalent and the packaging change does not create a new dosage form or delivery mechanism. A materially novel multidose system may require a 505(b)(2) pathway.
Is polymyxin B sulfate compatible with cationic ophthalmic preservatives?
Compatibility cannot be assumed. Because polymyxin B is cationic, preservatives and surfactants may affect potency, aggregation, adsorption, or ocular tolerability. Compatibility screening is required across concentration, pH, ionic strength, and container materials.
Would an ophthalmic gel have stronger patent value than a solution?
Potentially. A gel could support claims directed to residence time, dosing frequency, rheology, and delivery performance. It would also create additional risks involving blurred vision, dose uniformity, preservative distribution, and equivalence to the reference solution.
Can this combination be marketed as a veterinary ophthalmic product?
A veterinary product would require a separate regulatory strategy and species-specific safety and efficacy assessment. Human ophthalmic approval does not automatically authorize veterinary marketing.
Is a combination with a corticosteroid commercially attractive?
It can be attractive in selected ophthalmic indications, but the product would face a different benefit-risk assessment. Steroid combinations require control of contraindications, intraocular pressure risk, infection progression, and appropriate prescribing restrictions.
References
-
U.S. Food and Drug Administration. (2021). Polytrim: Polymyxin B sulfate and trimethoprim sulfate ophthalmic solution prescribing information. NDA 050592.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
